Benitec Biopharma INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Benitec Biopharma Inc. filed its annual report for the fiscal year ended June 30, 2026, detailing ongoing clinical development of its OPMD therapeutic, BB-301, and its financial position, which remains heavily reliant on future capital raises.
NASDAQ
Benitec Biopharma Inc. filed an amended annual report for fiscal year 2025 to include auditor signatures and updated certifications, while reporting increased cash and continued operational losses.
NASDAQ
Benitec Biopharma Inc. restated prior period financial statements due to share-based compensation errors, while continuing to advance its lead OPMD gene therapy, BB-301, through clinical trials.
NASDAQ
Benitec Biopharma Inc. has filed its annual 10-K report, highlighting advancements in its OPMD treatment program and financial activities.